nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Myelosuppression—Thiotepa—sarcoma	0.0052	0.037	CcSEcCtD
Ruxolitinib—Myelosuppression—Dactinomycin—sarcoma	0.00516	0.0368	CcSEcCtD
Ruxolitinib—Haemorrhage intracranial—Mitoxantrone—sarcoma	0.00513	0.0366	CcSEcCtD
Ruxolitinib—Myelosuppression—Vincristine—sarcoma	0.00461	0.0328	CcSEcCtD
Ruxolitinib—Myelosuppression—Mitoxantrone—sarcoma	0.00449	0.032	CcSEcCtD
Ruxolitinib—Myelosuppression—Etoposide—sarcoma	0.00374	0.0266	CcSEcCtD
Ruxolitinib—Contusion—Mitoxantrone—sarcoma	0.00241	0.0172	CcSEcCtD
Ruxolitinib—Bone pain—Vincristine—sarcoma	0.00226	0.0161	CcSEcCtD
Ruxolitinib—Bone pain—Mitoxantrone—sarcoma	0.0022	0.0157	CcSEcCtD
Ruxolitinib—Myelosuppression—Epirubicin—sarcoma	0.00209	0.0149	CcSEcCtD
Ruxolitinib—Myelosuppression—Doxorubicin—sarcoma	0.00194	0.0138	CcSEcCtD
Ruxolitinib—RPS6KA6—tendon—sarcoma	0.00187	0.00555	CbGeAlD
Ruxolitinib—JAK3—hematopoietic system—sarcoma	0.00182	0.0054	CbGeAlD
Ruxolitinib—DAPK2—seminal vesicle—sarcoma	0.00181	0.00539	CbGeAlD
Ruxolitinib—JAK1—hematopoietic system—sarcoma	0.00181	0.00537	CbGeAlD
Ruxolitinib—PLK4—hematopoietic system—sarcoma	0.00179	0.00534	CbGeAlD
Ruxolitinib—PLK3—cardiac atrium—sarcoma	0.00179	0.00532	CbGeAlD
Ruxolitinib—JAK2—mammary gland—sarcoma	0.00178	0.0053	CbGeAlD
Ruxolitinib—BMPR2—myometrium—sarcoma	0.00176	0.00523	CbGeAlD
Ruxolitinib—JAK3—connective tissue—sarcoma	0.00175	0.0052	CbGeAlD
Ruxolitinib—ROCK1—embryo—sarcoma	0.00174	0.00518	CbGeAlD
Ruxolitinib—JAK1—connective tissue—sarcoma	0.00174	0.00517	CbGeAlD
Ruxolitinib—PRKG2—testis—sarcoma	0.00172	0.00512	CbGeAlD
Ruxolitinib—MAP3K3—mammary gland—sarcoma	0.00172	0.00511	CbGeAlD
Ruxolitinib—STK16—hematopoietic system—sarcoma	0.0017	0.00504	CbGeAlD
Ruxolitinib—CLK2—seminal vesicle—sarcoma	0.00169	0.00502	CbGeAlD
Ruxolitinib—HIPK2—hematopoietic system—sarcoma	0.00169	0.00501	CbGeAlD
Ruxolitinib—PRKG2—liver—sarcoma	0.00163	0.00484	CbGeAlD
Ruxolitinib—HIPK2—connective tissue—sarcoma	0.00162	0.00483	CbGeAlD
Ruxolitinib—PRKCE—testis—sarcoma	0.00161	0.00478	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—sarcoma	0.00159	0.00473	CbGeAlD
Ruxolitinib—CAMK2G—myometrium—sarcoma	0.00157	0.00468	CbGeAlD
Ruxolitinib—JAK1—skin of body—sarcoma	0.00157	0.00467	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Thiotepa—sarcoma	0.00156	0.0111	CcSEcCtD
Ruxolitinib—LRRK2—myometrium—sarcoma	0.00156	0.00464	CbGeAlD
Ruxolitinib—ROCK1—hematopoietic system—sarcoma	0.00156	0.00463	CbGeAlD
Ruxolitinib—PLK1—testis—sarcoma	0.00155	0.0046	CbGeAlD
Ruxolitinib—RPS6KA6—testis—sarcoma	0.00155	0.0046	CbGeAlD
Ruxolitinib—MAST1—testis—sarcoma	0.00155	0.0046	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Mitoxantrone—sarcoma	0.00153	0.0109	CcSEcCtD
Ruxolitinib—PRKCE—liver—sarcoma	0.00152	0.00452	CbGeAlD
Ruxolitinib—NUAK2—seminal vesicle—sarcoma	0.00152	0.00452	CbGeAlD
Ruxolitinib—DYRK1A—hematopoietic system—sarcoma	0.00152	0.00451	CbGeAlD
Ruxolitinib—BMPR2—hematopoietic system—sarcoma	0.00151	0.00449	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—sarcoma	0.0015	0.00445	CbGeAlD
Ruxolitinib—DCLK3—testis—sarcoma	0.00147	0.00436	CbGeAlD
Ruxolitinib—PLK1—liver—sarcoma	0.00146	0.00435	CbGeAlD
Ruxolitinib—RPS6KA6—liver—sarcoma	0.00146	0.00435	CbGeAlD
Ruxolitinib—CAMK1—tendon—sarcoma	0.00146	0.00433	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—sarcoma	0.00145	0.00433	CbGeAlD
Ruxolitinib—Pancytopenia—Thiotepa—sarcoma	0.00145	0.0103	CcSEcCtD
Ruxolitinib—Pancytopenia—Dactinomycin—sarcoma	0.00144	0.0103	CcSEcCtD
Ruxolitinib—DAPK3—smooth muscle tissue—sarcoma	0.00143	0.00424	CbGeAlD
Ruxolitinib—Neutropenia—Dactinomycin—sarcoma	0.00142	0.0101	CcSEcCtD
Ruxolitinib—MAP3K7—myometrium—sarcoma	0.00142	0.00421	CbGeAlD
Ruxolitinib—MARK2—tendon—sarcoma	0.00141	0.00421	CbGeAlD
Ruxolitinib—LRRK2—seminal vesicle—sarcoma	0.00141	0.00419	CbGeAlD
Ruxolitinib—Weight increased—Thiotepa—sarcoma	0.00139	0.00991	CcSEcCtD
Ruxolitinib—TYK2—myometrium—sarcoma	0.00139	0.00414	CbGeAlD
Ruxolitinib—MKNK2—myometrium—sarcoma	0.00137	0.00408	CbGeAlD
Ruxolitinib—JAK1—cardiac atrium—sarcoma	0.00137	0.00408	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—sarcoma	0.00137	0.00407	CbGeAlD
Ruxolitinib—JAK1—uterus—sarcoma	0.00136	0.00406	CbGeAlD
Ruxolitinib—DCLK1—uterus—sarcoma	0.00136	0.00406	CbGeAlD
Ruxolitinib—Infestation NOS—Thiotepa—sarcoma	0.00136	0.00971	CcSEcCtD
Ruxolitinib—Infestation—Thiotepa—sarcoma	0.00136	0.00971	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Mitoxantrone—sarcoma	0.00135	0.0096	CcSEcCtD
Ruxolitinib—LRRK2—hematopoietic system—sarcoma	0.00134	0.00398	CbGeAlD
Ruxolitinib—CAMK1D—cardiac atrium—sarcoma	0.00134	0.00398	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—sarcoma	0.00133	0.00396	CbGeAlD
Ruxolitinib—BMPR2—skin of body—sarcoma	0.00131	0.00391	CbGeAlD
Ruxolitinib—TAOK2—tendon—sarcoma	0.00131	0.00389	CbGeAlD
Ruxolitinib—DAPK2—cardiac atrium—sarcoma	0.00131	0.00389	CbGeAlD
Ruxolitinib—Herpes zoster—Epirubicin—sarcoma	0.0013	0.00929	CcSEcCtD
Ruxolitinib—BMP2K—connective tissue—sarcoma	0.0013	0.00387	CbGeAlD
Ruxolitinib—Haematuria—Thiotepa—sarcoma	0.0013	0.00926	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Thiotepa—sarcoma	0.00129	0.00919	CcSEcCtD
Ruxolitinib—PLK3—testis—sarcoma	0.00129	0.00384	CbGeAlD
Ruxolitinib—Pancytopenia—Vincristine—sarcoma	0.00129	0.00917	CcSEcCtD
Ruxolitinib—RET—embryo—sarcoma	0.00129	0.00383	CbGeAlD
Ruxolitinib—Epistaxis—Thiotepa—sarcoma	0.00129	0.00916	CcSEcCtD
Ruxolitinib—MAP3K7—seminal vesicle—sarcoma	0.00128	0.00381	CbGeAlD
Ruxolitinib—JAK3—lymphoid tissue—sarcoma	0.00128	0.00381	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—sarcoma	0.00127	0.00378	CbGeAlD
Ruxolitinib—Neutropenia—Vincristine—sarcoma	0.00127	0.00903	CcSEcCtD
Ruxolitinib—JAK2—myometrium—sarcoma	0.00127	0.00376	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—sarcoma	0.00126	0.00376	CbGeAlD
Ruxolitinib—TYK2—seminal vesicle—sarcoma	0.00126	0.00374	CbGeAlD
Ruxolitinib—Pancytopenia—Mitoxantrone—sarcoma	0.00125	0.00893	CcSEcCtD
Ruxolitinib—LTK—testis—sarcoma	0.00125	0.00371	CbGeAlD
Ruxolitinib—MKNK2—seminal vesicle—sarcoma	0.00124	0.00369	CbGeAlD
Ruxolitinib—Neutropenia—Mitoxantrone—sarcoma	0.00124	0.0088	CcSEcCtD
Ruxolitinib—Haemoglobin—Thiotepa—sarcoma	0.00123	0.00876	CcSEcCtD
Ruxolitinib—DAPK3—cardiac atrium—sarcoma	0.00123	0.00366	CbGeAlD
Ruxolitinib—MAP3K2—hematopoietic system—sarcoma	0.00123	0.00365	CbGeAlD
Ruxolitinib—Weight decreased—Vincristine—sarcoma	0.00123	0.00874	CcSEcCtD
Ruxolitinib—Haemorrhage—Thiotepa—sarcoma	0.00122	0.00872	CcSEcCtD
Ruxolitinib—DAPK3—uterus—sarcoma	0.00122	0.00364	CbGeAlD
Ruxolitinib—MAP3K3—myometrium—sarcoma	0.00122	0.00363	CbGeAlD
Ruxolitinib—PLK3—liver—sarcoma	0.00122	0.00363	CbGeAlD
Ruxolitinib—CLK2—cardiac atrium—sarcoma	0.00122	0.00362	CbGeAlD
Ruxolitinib—JAK2—embryo—sarcoma	0.00122	0.00362	CbGeAlD
Ruxolitinib—CAMK1—testis—sarcoma	0.00121	0.00359	CbGeAlD
Ruxolitinib—Herpes zoster—Doxorubicin—sarcoma	0.00121	0.00859	CcSEcCtD
Ruxolitinib—Weight increased—Mitoxantrone—sarcoma	0.0012	0.00856	CcSEcCtD
Ruxolitinib—Weight decreased—Mitoxantrone—sarcoma	0.0012	0.00851	CcSEcCtD
Ruxolitinib—JAK1—tendon—sarcoma	0.0012	0.00355	CbGeAlD
Ruxolitinib—DCLK1—tendon—sarcoma	0.0012	0.00355	CbGeAlD
Ruxolitinib—TYK2—hematopoietic system—sarcoma	0.00119	0.00355	CbGeAlD
Ruxolitinib—STK16—lymphoid tissue—sarcoma	0.00119	0.00355	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—sarcoma	0.00119	0.00353	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—sarcoma	0.00118	0.00352	CbGeAlD
Ruxolitinib—IRAK1—hematopoietic system—sarcoma	0.00118	0.00351	CbGeAlD
Ruxolitinib—MKNK2—hematopoietic system—sarcoma	0.00118	0.00351	CbGeAlD
Ruxolitinib—MARK2—testis—sarcoma	0.00117	0.00348	CbGeAlD
Ruxolitinib—CAMK1D—tendon—sarcoma	0.00117	0.00347	CbGeAlD
Ruxolitinib—PRKCE—lymph node—sarcoma	0.00117	0.00347	CbGeAlD
Ruxolitinib—PHKG2—tendon—sarcoma	0.00116	0.00345	CbGeAlD
Ruxolitinib—JAK1—bone marrow—sarcoma	0.00116	0.00344	CbGeAlD
Ruxolitinib—PLK4—bone marrow—sarcoma	0.00115	0.00342	CbGeAlD
Ruxolitinib—TYK2—connective tissue—sarcoma	0.00115	0.00342	CbGeAlD
Ruxolitinib—RET—hematopoietic system—sarcoma	0.00115	0.00342	CbGeAlD
Ruxolitinib—BMPR2—cardiac atrium—sarcoma	0.00115	0.00341	CbGeAlD
Ruxolitinib—Urinary tract infection—Mitoxantrone—sarcoma	0.00115	0.00815	CcSEcCtD
Ruxolitinib—JAK2—seminal vesicle—sarcoma	0.00114	0.0034	CbGeAlD
Ruxolitinib—BMPR2—uterus—sarcoma	0.00114	0.00339	CbGeAlD
Ruxolitinib—CAMK1—liver—sarcoma	0.00114	0.00339	CbGeAlD
Ruxolitinib—DAPK2—tendon—sarcoma	0.00114	0.00339	CbGeAlD
Ruxolitinib—MKNK2—connective tissue—sarcoma	0.00113	0.00337	CbGeAlD
Ruxolitinib—CLK2—lymphoid tissue—sarcoma	0.00113	0.00336	CbGeAlD
Ruxolitinib—Haematuria—Mitoxantrone—sarcoma	0.00112	0.008	CcSEcCtD
Ruxolitinib—STK16—tendon—sarcoma	0.00112	0.00334	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—sarcoma	0.00112	0.00799	CcSEcCtD
Ruxolitinib—RPS6KA6—lymph node—sarcoma	0.00112	0.00333	CbGeAlD
Ruxolitinib—PLK1—lymph node—sarcoma	0.00112	0.00333	CbGeAlD
Ruxolitinib—HIPK2—tendon—sarcoma	0.00112	0.00332	CbGeAlD
Ruxolitinib—TAOK3—myometrium—sarcoma	0.00111	0.00331	CbGeAlD
Ruxolitinib—RET—connective tissue—sarcoma	0.00111	0.00329	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—sarcoma	0.0011	0.00328	CbGeAlD
Ruxolitinib—MAP3K3—seminal vesicle—sarcoma	0.0011	0.00328	CbGeAlD
Ruxolitinib—ROCK1—lymphoid tissue—sarcoma	0.0011	0.00326	CbGeAlD
Ruxolitinib—JAK2—hematopoietic system—sarcoma	0.00109	0.00323	CbGeAlD
Ruxolitinib—TAOK2—testis—sarcoma	0.00108	0.00322	CbGeAlD
Ruxolitinib—DAPK3—tendon—sarcoma	0.00107	0.00319	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—sarcoma	0.00107	0.00319	CbGeAlD
Ruxolitinib—DYRK1A—lymphoid tissue—sarcoma	0.00107	0.00318	CbGeAlD
Ruxolitinib—Malnutrition—Thiotepa—sarcoma	0.00107	0.00759	CcSEcCtD
Ruxolitinib—BMPR2—lymphoid tissue—sarcoma	0.00106	0.00316	CbGeAlD
Ruxolitinib—Haemoglobin—Mitoxantrone—sarcoma	0.00106	0.00757	CcSEcCtD
Ruxolitinib—CLK2—tendon—sarcoma	0.00106	0.00316	CbGeAlD
Ruxolitinib—Haemorrhage—Mitoxantrone—sarcoma	0.00106	0.00753	CcSEcCtD
Ruxolitinib—TYK2—smooth muscle tissue—sarcoma	0.00105	0.00313	CbGeAlD
Ruxolitinib—MAP3K3—hematopoietic system—sarcoma	0.00105	0.00311	CbGeAlD
Ruxolitinib—JAK2—connective tissue—sarcoma	0.00105	0.00311	CbGeAlD
Ruxolitinib—Pancytopenia—Etoposide—sarcoma	0.00104	0.00743	CcSEcCtD
Ruxolitinib—TYK2—skin of body—sarcoma	0.00104	0.00309	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—sarcoma	0.00104	0.00309	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—sarcoma	0.00104	0.00309	CbGeAlD
Ruxolitinib—CLK2—bone marrow—sarcoma	0.00103	0.00306	CbGeAlD
Ruxolitinib—Neutropenia—Etoposide—sarcoma	0.00103	0.00732	CcSEcCtD
Ruxolitinib—PLK1—Teniposide—Etoposide—sarcoma	0.00103	0.0875	CbGdCrCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—sarcoma	0.00103	0.0875	CbGdCrCtD
Ruxolitinib—Bone pain—Epirubicin—sarcoma	0.00103	0.0073	CcSEcCtD
Ruxolitinib—TAOK2—liver—sarcoma	0.00102	0.00305	CbGeAlD
Ruxolitinib—CAMK2G—uterus—sarcoma	0.00102	0.00304	CbGeAlD
Ruxolitinib—TAOK3—seminal vesicle—sarcoma	0.001	0.00299	CbGeAlD
Ruxolitinib—BMPR2—tendon—sarcoma	0.001	0.00297	CbGeAlD
Ruxolitinib—JAK3—testis—sarcoma	0.000996	0.00296	CbGeAlD
Ruxolitinib—JAK1—testis—sarcoma	0.00099	0.00294	CbGeAlD
Ruxolitinib—DCLK1—testis—sarcoma	0.00099	0.00294	CbGeAlD
Ruxolitinib—Anaemia—Thiotepa—sarcoma	0.000985	0.00702	CcSEcCtD
Ruxolitinib—PLK4—testis—sarcoma	0.000984	0.00293	CbGeAlD
Ruxolitinib—Infestation NOS—Etoposide—sarcoma	0.00098	0.00698	CcSEcCtD
Ruxolitinib—Infestation—Etoposide—sarcoma	0.00098	0.00698	CcSEcCtD
Ruxolitinib—Anaemia—Dactinomycin—sarcoma	0.000978	0.00696	CcSEcCtD
Ruxolitinib—CAMK1D—testis—sarcoma	0.000966	0.00287	CbGeAlD
Ruxolitinib—PHKG2—testis—sarcoma	0.00096	0.00286	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—sarcoma	0.000957	0.00285	CbGeAlD
Ruxolitinib—TAOK3—hematopoietic system—sarcoma	0.000955	0.00284	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—sarcoma	0.000948	0.00675	CcSEcCtD
Ruxolitinib—JAK2—skin of body—sarcoma	0.000945	0.00281	CbGeAlD
Ruxolitinib—DAPK2—testis—sarcoma	0.000944	0.00281	CbGeAlD
Ruxolitinib—JAK1—liver—sarcoma	0.000936	0.00278	CbGeAlD
Ruxolitinib—PLK3—lymph node—sarcoma	0.000935	0.00278	CbGeAlD
Ruxolitinib—STK16—testis—sarcoma	0.000929	0.00276	CbGeAlD
Ruxolitinib—MAP3K2—uterus—sarcoma	0.000927	0.00276	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Etoposide—sarcoma	0.000927	0.0066	CcSEcCtD
Ruxolitinib—NUAK2—bone marrow—sarcoma	0.000926	0.00275	CbGeAlD
Ruxolitinib—HIPK2—testis—sarcoma	0.000924	0.00275	CbGeAlD
Ruxolitinib—MAP3K7—cardiac atrium—sarcoma	0.000924	0.00275	CbGeAlD
Ruxolitinib—TAOK3—connective tissue—sarcoma	0.000919	0.00273	CbGeAlD
Ruxolitinib—MAP3K7—uterus—sarcoma	0.000919	0.00273	CbGeAlD
Ruxolitinib—CAMK1D—liver—sarcoma	0.000913	0.00272	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—sarcoma	0.00091	0.00271	CbGeAlD
Ruxolitinib—PHKG2—liver—sarcoma	0.000908	0.0027	CbGeAlD
Ruxolitinib—TYK2—cardiac atrium—sarcoma	0.000907	0.0027	CbGeAlD
Ruxolitinib—MAP3K19—testis—sarcoma	0.000905	0.00269	CbGeAlD
Ruxolitinib—LTK—lymph node—sarcoma	0.000903	0.00269	CbGeAlD
Ruxolitinib—TYK2—uterus—sarcoma	0.000902	0.00268	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000901	0.00642	CcSEcCtD
Ruxolitinib—MKNK2—cardiac atrium—sarcoma	0.000895	0.00266	CbGeAlD
Ruxolitinib—BMP2K—tendon—sarcoma	0.000895	0.00266	CbGeAlD
Ruxolitinib—CAMK2G—tendon—sarcoma	0.000895	0.00266	CbGeAlD
Ruxolitinib—MKNK2—uterus—sarcoma	0.00089	0.00265	CbGeAlD
Ruxolitinib—DAPK3—testis—sarcoma	0.000888	0.00264	CbGeAlD
Ruxolitinib—LRRK2—tendon—sarcoma	0.000887	0.00264	CbGeAlD
Ruxolitinib—CLK2—testis—sarcoma	0.000879	0.00262	CbGeAlD
Ruxolitinib—STK16—liver—sarcoma	0.000878	0.00261	CbGeAlD
Ruxolitinib—CAMK1—lymph node—sarcoma	0.000875	0.0026	CbGeAlD
Ruxolitinib—Anaemia—Vincristine—sarcoma	0.000874	0.00622	CcSEcCtD
Ruxolitinib—HIPK2—liver—sarcoma	0.000874	0.0026	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—sarcoma	0.000867	0.00258	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—sarcoma	0.000867	0.00258	CbGeAlD
Ruxolitinib—Infection—Thiotepa—sarcoma	0.000864	0.00615	CcSEcCtD
Ruxolitinib—MAP3K2—lymphoid tissue—sarcoma	0.000864	0.00257	CbGeAlD
Ruxolitinib—LRRK2—bone marrow—sarcoma	0.000859	0.00255	CbGeAlD
Ruxolitinib—Infection—Dactinomycin—sarcoma	0.000858	0.00611	CcSEcCtD
Ruxolitinib—Nervous system disorder—Thiotepa—sarcoma	0.000853	0.00608	CcSEcCtD
Ruxolitinib—ROCK1—testis—sarcoma	0.000852	0.00253	CbGeAlD
Ruxolitinib—Thrombocytopenia—Thiotepa—sarcoma	0.000852	0.00607	CcSEcCtD
Ruxolitinib—Anaemia—Mitoxantrone—sarcoma	0.000851	0.00606	CcSEcCtD
Ruxolitinib—MARK2—lymph node—sarcoma	0.000849	0.00252	CbGeAlD
Ruxolitinib—Thrombocytopenia—Dactinomycin—sarcoma	0.000845	0.00602	CcSEcCtD
Ruxolitinib—Skin disorder—Thiotepa—sarcoma	0.000845	0.00602	CcSEcCtD
Ruxolitinib—TYK2—lymphoid tissue—sarcoma	0.000841	0.0025	CbGeAlD
Ruxolitinib—DAPK3—liver—sarcoma	0.000839	0.0025	CbGeAlD
Ruxolitinib—CLK2—liver—sarcoma	0.000831	0.00247	CbGeAlD
Ruxolitinib—DYRK1A—testis—sarcoma	0.000831	0.00247	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—sarcoma	0.00083	0.00247	CbGeAlD
Ruxolitinib—BMPR2—testis—sarcoma	0.000828	0.00246	CbGeAlD
Ruxolitinib—JAK2—cardiac atrium—sarcoma	0.000825	0.00245	CbGeAlD
Ruxolitinib—RET—lymphoid tissue—sarcoma	0.000809	0.00241	CbGeAlD
Ruxolitinib—ROCK1—liver—sarcoma	0.000806	0.0024	CbGeAlD
Ruxolitinib—MAP3K7—tendon—sarcoma	0.000805	0.00239	CbGeAlD
Ruxolitinib—MAP3K3—cardiac atrium—sarcoma	0.000795	0.00236	CbGeAlD
Ruxolitinib—NUAK2—testis—sarcoma	0.000791	0.00235	CbGeAlD
Ruxolitinib—TYK2—tendon—sarcoma	0.00079	0.00235	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—sarcoma	0.000787	0.00234	CbGeAlD
Ruxolitinib—DYRK1A—liver—sarcoma	0.000786	0.00234	CbGeAlD
Ruxolitinib—TAOK2—lymph node—sarcoma	0.000786	0.00234	CbGeAlD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—sarcoma	0.000783	0.0668	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—sarcoma	0.000783	0.0668	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—sarcoma	0.000783	0.0668	CbGdCrCtD
Ruxolitinib—BMPR2—liver—sarcoma	0.000783	0.00233	CbGeAlD
Ruxolitinib—MKNK2—tendon—sarcoma	0.00078	0.00232	CbGeAlD
Ruxolitinib—IRAK1—tendon—sarcoma	0.00078	0.00232	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—sarcoma	0.00078	0.00232	CbGeAlD
Ruxolitinib—Infection—Vincristine—sarcoma	0.000766	0.00546	CcSEcCtD
Ruxolitinib—TYK2—bone marrow—sarcoma	0.000766	0.00228	CbGeAlD
Ruxolitinib—JAK2—lymphoid tissue—sarcoma	0.000765	0.00227	CbGeAlD
Ruxolitinib—RET—tendon—sarcoma	0.000761	0.00226	CbGeAlD
Ruxolitinib—Nervous system disorder—Vincristine—sarcoma	0.000757	0.00539	CcSEcCtD
Ruxolitinib—IRAK1—bone marrow—sarcoma	0.000756	0.00225	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—sarcoma	0.000756	0.00225	CbGeAlD
Ruxolitinib—Thrombocytopenia—Vincristine—sarcoma	0.000755	0.00538	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Thiotepa—sarcoma	0.000751	0.00535	CcSEcCtD
Ruxolitinib—Fatigue—Thiotepa—sarcoma	0.00075	0.00534	CcSEcCtD
Ruxolitinib—NUAK2—liver—sarcoma	0.000748	0.00222	CbGeAlD
Ruxolitinib—Infection—Mitoxantrone—sarcoma	0.000746	0.00532	CcSEcCtD
Ruxolitinib—Fatigue—Dactinomycin—sarcoma	0.000744	0.0053	CcSEcCtD
Ruxolitinib—CAMK2G—testis—sarcoma	0.000741	0.0022	CbGeAlD
Ruxolitinib—BMP2K—testis—sarcoma	0.000741	0.0022	CbGeAlD
Ruxolitinib—Thrombocytopenia—Mitoxantrone—sarcoma	0.000736	0.00524	CcSEcCtD
Ruxolitinib—LRRK2—testis—sarcoma	0.000734	0.00218	CbGeAlD
Ruxolitinib—Skin disorder—Mitoxantrone—sarcoma	0.00073	0.0052	CcSEcCtD
Ruxolitinib—TAOK3—cardiac atrium—sarcoma	0.000725	0.00216	CbGeAlD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—sarcoma	0.000724	0.0618	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—sarcoma	0.000724	0.0618	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—sarcoma	0.000724	0.0618	CbGdCrCtD
Ruxolitinib—JAK3—lymph node—sarcoma	0.000722	0.00215	CbGeAlD
Ruxolitinib—TAOK3—uterus—sarcoma	0.000721	0.00214	CbGeAlD
Ruxolitinib—JAK2—tendon—sarcoma	0.000719	0.00214	CbGeAlD
Ruxolitinib—DCLK1—lymph node—sarcoma	0.000717	0.00213	CbGeAlD
Ruxolitinib—JAK1—lymph node—sarcoma	0.000717	0.00213	CbGeAlD
Ruxolitinib—PLK4—lymph node—sarcoma	0.000713	0.00212	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—sarcoma	0.000713	0.00508	CcSEcCtD
Ruxolitinib—Anaemia—Etoposide—sarcoma	0.000708	0.00504	CcSEcCtD
Ruxolitinib—BMP2K—liver—sarcoma	0.0007	0.00208	CbGeAlD
Ruxolitinib—CAMK2G—liver—sarcoma	0.0007	0.00208	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—sarcoma	0.0007	0.00208	CbGeAlD
Ruxolitinib—JAK2—bone marrow—sarcoma	0.000697	0.00207	CbGeAlD
Ruxolitinib—PHKG2—lymph node—sarcoma	0.000696	0.00207	CbGeAlD
Ruxolitinib—LRRK2—liver—sarcoma	0.000694	0.00206	CbGeAlD
Ruxolitinib—MAP3K3—tendon—sarcoma	0.000693	0.00206	CbGeAlD
Ruxolitinib—Body temperature increased—Thiotepa—sarcoma	0.000688	0.0049	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—sarcoma	0.000684	0.00204	CbGeAlD
Ruxolitinib—Body temperature increased—Dactinomycin—sarcoma	0.000683	0.00486	CcSEcCtD
Ruxolitinib—STK16—lymph node—sarcoma	0.000673	0.002	CbGeAlD
Ruxolitinib—MAP3K2—testis—sarcoma	0.000673	0.002	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—sarcoma	0.000672	0.002	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—sarcoma	0.000671	0.002	CbGeAlD
Ruxolitinib—HIPK2—lymph node—sarcoma	0.00067	0.00199	CbGeAlD
Ruxolitinib—MAP3K7—testis—sarcoma	0.000667	0.00198	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Vincristine—sarcoma	0.000666	0.00474	CcSEcCtD
Ruxolitinib—Fatigue—Vincristine—sarcoma	0.000665	0.00474	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.00066	0.0047	CcSEcCtD
Ruxolitinib—TYK2—testis—sarcoma	0.000654	0.00195	CbGeAlD
Ruxolitinib—Fatigue—Mitoxantrone—sarcoma	0.000648	0.00461	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000647	0.00461	CcSEcCtD
Ruxolitinib—IRAK1—testis—sarcoma	0.000646	0.00192	CbGeAlD
Ruxolitinib—MKNK2—testis—sarcoma	0.000646	0.00192	CbGeAlD
Ruxolitinib—DAPK3—lymph node—sarcoma	0.000644	0.00191	CbGeAlD
Ruxolitinib—CLK2—lymph node—sarcoma	0.000637	0.0019	CbGeAlD
Ruxolitinib—MAP3K2—liver—sarcoma	0.000636	0.00189	CbGeAlD
Ruxolitinib—TAOK3—tendon—sarcoma	0.000632	0.00188	CbGeAlD
Ruxolitinib—MAP3K7—liver—sarcoma	0.00063	0.00187	CbGeAlD
Ruxolitinib—RET—testis—sarcoma	0.00063	0.00187	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000629	0.00448	CcSEcCtD
Ruxolitinib—Asthenia—Thiotepa—sarcoma	0.000624	0.00444	CcSEcCtD
Ruxolitinib—Infection—Etoposide—sarcoma	0.000621	0.00442	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—sarcoma	0.00062	0.00441	CcSEcCtD
Ruxolitinib—TYK2—liver—sarcoma	0.000619	0.00184	CbGeAlD
Ruxolitinib—Pruritus—Thiotepa—sarcoma	0.000616	0.00438	CcSEcCtD
Ruxolitinib—TAOK3—bone marrow—sarcoma	0.000612	0.00182	CbGeAlD
Ruxolitinib—Thrombocytopenia—Etoposide—sarcoma	0.000612	0.00436	CcSEcCtD
Ruxolitinib—MKNK2—liver—sarcoma	0.000611	0.00182	CbGeAlD
Ruxolitinib—IRAK1—liver—sarcoma	0.000611	0.00182	CbGeAlD
Ruxolitinib—Body temperature increased—Vincristine—sarcoma	0.00061	0.00434	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—sarcoma	0.000607	0.00432	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—sarcoma	0.000603	0.00179	CbGeAlD
Ruxolitinib—BMPR2—lymph node—sarcoma	0.0006	0.00178	CbGeAlD
Ruxolitinib—JAK2—testis—sarcoma	0.000595	0.00177	CbGeAlD
Ruxolitinib—Body temperature increased—Mitoxantrone—sarcoma	0.000594	0.00423	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—sarcoma	0.000585	0.00417	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000582	0.00414	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—sarcoma	0.000576	0.0041	CcSEcCtD
Ruxolitinib—Dizziness—Thiotepa—sarcoma	0.000575	0.0041	CcSEcCtD
Ruxolitinib—MAP3K3—testis—sarcoma	0.000574	0.00171	CbGeAlD
Ruxolitinib—NUAK2—lymph node—sarcoma	0.000574	0.00171	CbGeAlD
Ruxolitinib—JAK2—liver—sarcoma	0.000563	0.00167	CbGeAlD
Ruxolitinib—Weight increased—Epirubicin—sarcoma	0.000561	0.00399	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—sarcoma	0.000557	0.00397	CcSEcCtD
Ruxolitinib—Asthenia—Vincristine—sarcoma	0.000554	0.00394	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—sarcoma	0.000549	0.00391	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—sarcoma	0.000549	0.00391	CcSEcCtD
Ruxolitinib—Headache—Thiotepa—sarcoma	0.000545	0.00388	CcSEcCtD
Ruxolitinib—MAP3K3—liver—sarcoma	0.000543	0.00161	CbGeAlD
Ruxolitinib—Pancytopenia—Doxorubicin—sarcoma	0.000541	0.00385	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—sarcoma	0.00054	0.00384	CcSEcCtD
Ruxolitinib—Asthenia—Mitoxantrone—sarcoma	0.000539	0.00384	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—sarcoma	0.000539	0.00384	CcSEcCtD
Ruxolitinib—BMP2K—lymph node—sarcoma	0.000537	0.0016	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—sarcoma	0.000537	0.0016	CbGeAlD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—sarcoma	0.000535	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—sarcoma	0.000535	0.0456	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—sarcoma	0.000535	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—sarcoma	0.000535	0.0456	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—sarcoma	0.000535	0.0456	CbGdCrCtD
Ruxolitinib—Urinary tract infection—Epirubicin—sarcoma	0.000534	0.0038	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—sarcoma	0.000533	0.0038	CcSEcCtD
Ruxolitinib—LRRK2—lymph node—sarcoma	0.000532	0.00158	CbGeAlD
Ruxolitinib—Haematuria—Epirubicin—sarcoma	0.000524	0.00373	CcSEcCtD
Ruxolitinib—TAOK3—testis—sarcoma	0.000523	0.00156	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Epirubicin—sarcoma	0.00052	0.0037	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—sarcoma	0.000519	0.00369	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—sarcoma	0.000518	0.00369	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—sarcoma	0.000516	0.00367	CcSEcCtD
Ruxolitinib—Dizziness—Vincristine—sarcoma	0.00051	0.00363	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—sarcoma	0.000508	0.00362	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—sarcoma	0.000508	0.00362	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—sarcoma	0.000496	0.00353	CcSEcCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—sarcoma	0.000495	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—sarcoma	0.000495	0.0422	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—sarcoma	0.000495	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—sarcoma	0.000495	0.0422	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—sarcoma	0.000495	0.0422	CbGdCrCtD
Ruxolitinib—TAOK3—liver—sarcoma	0.000495	0.00147	CbGeAlD
Ruxolitinib—Body temperature increased—Etoposide—sarcoma	0.000494	0.00352	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—sarcoma	0.000494	0.00352	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—sarcoma	0.000493	0.00351	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—sarcoma	0.000488	0.00145	CbGeAlD
Ruxolitinib—Haematuria—Doxorubicin—sarcoma	0.000485	0.00345	CcSEcCtD
Ruxolitinib—Headache—Vincristine—sarcoma	0.000483	0.00344	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—sarcoma	0.000483	0.00144	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—sarcoma	0.000481	0.00342	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—sarcoma	0.000479	0.00341	CcSEcCtD
Ruxolitinib—TYK2—lymph node—sarcoma	0.000474	0.00141	CbGeAlD
Ruxolitinib—Headache—Mitoxantrone—sarcoma	0.000471	0.00335	CcSEcCtD
Ruxolitinib—MKNK2—lymph node—sarcoma	0.000468	0.00139	CbGeAlD
Ruxolitinib—IRAK1—lymph node—sarcoma	0.000468	0.00139	CbGeAlD
Ruxolitinib—Haemoglobin—Doxorubicin—sarcoma	0.000459	0.00327	CcSEcCtD
Ruxolitinib—RET—lymph node—sarcoma	0.000457	0.00136	CbGeAlD
Ruxolitinib—Haemorrhage—Doxorubicin—sarcoma	0.000456	0.00325	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—sarcoma	0.000448	0.00319	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—sarcoma	0.000442	0.00315	CcSEcCtD
Ruxolitinib—JAK2—lymph node—sarcoma	0.000432	0.00128	CbGeAlD
Ruxolitinib—Malnutrition—Epirubicin—sarcoma	0.000429	0.00306	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—sarcoma	0.000423	0.00301	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—sarcoma	0.000416	0.00124	CbGeAlD
Ruxolitinib—Dizziness—Etoposide—sarcoma	0.000413	0.00294	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—sarcoma	0.000397	0.00283	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—sarcoma	0.000397	0.00283	CcSEcCtD
Ruxolitinib—Headache—Etoposide—sarcoma	0.000392	0.00279	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—sarcoma	0.000391	0.00279	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—sarcoma	0.000379	0.00113	CbGeAlD
Ruxolitinib—Anaemia—Doxorubicin—sarcoma	0.000367	0.00261	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000363	0.00258	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—sarcoma	0.000348	0.00248	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—sarcoma	0.000344	0.00245	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—sarcoma	0.000343	0.00244	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—sarcoma	0.00034	0.00242	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000336	0.00239	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—sarcoma	0.000322	0.00229	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—sarcoma	0.000318	0.00226	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—sarcoma	0.000317	0.00226	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—sarcoma	0.000315	0.00224	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—sarcoma	0.000302	0.00215	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—sarcoma	0.000302	0.00215	CcSEcCtD
Ruxolitinib—CYP3A4—hematopoietic system—sarcoma	0.00029	0.000863	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00028	0.00199	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—sarcoma	0.000279	0.00199	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—sarcoma	0.000277	0.00197	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—sarcoma	0.000256	0.00182	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—sarcoma	0.000251	0.00179	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—sarcoma	0.000248	0.00176	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—sarcoma	0.000233	0.00166	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—sarcoma	0.000232	0.00165	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—sarcoma	0.000229	0.00163	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—sarcoma	0.000219	0.00156	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—sarcoma	0.000214	0.00153	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—sarcoma	0.000203	0.00145	CcSEcCtD
Ruxolitinib—CYP3A4—liver—sarcoma	0.00015	0.000447	CbGeAlD
Ruxolitinib—ROCK1—Signaling by GPCR—NRAS—sarcoma	1.71e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ATF1—sarcoma	1.71e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—sarcoma	1.71e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PDGFRA—sarcoma	1.71e-05	3.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NRAS—sarcoma	1.7e-05	3.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CTNNB1—sarcoma	1.69e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL2—sarcoma	1.69e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KRAS—sarcoma	1.69e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FOXO1—sarcoma	1.68e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—sarcoma	1.68e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PDGFRB—sarcoma	1.68e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KRAS—sarcoma	1.68e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—sarcoma	1.67e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—sarcoma	1.67e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PDGFRA—sarcoma	1.66e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CREB1—sarcoma	1.66e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—SRC—sarcoma	1.65e-05	3.23e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCND1—sarcoma	1.64e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—JUN—sarcoma	1.64e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FOXO1—sarcoma	1.63e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PDGFRB—sarcoma	1.63e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CREB1—sarcoma	1.63e-05	3.18e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CTNNB1—sarcoma	1.63e-05	3.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KRAS—sarcoma	1.61e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MDM2—sarcoma	1.61e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PDGFRA—sarcoma	1.61e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—sarcoma	1.6e-05	3.13e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—sarcoma	1.59e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MDM2—sarcoma	1.59e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KRAS—sarcoma	1.59e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NRAS—sarcoma	1.59e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—SRC—sarcoma	1.59e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—sarcoma	1.58e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—sarcoma	1.57e-05	3.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CREB1—sarcoma	1.57e-05	3.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MDM2—sarcoma	1.56e-05	3.06e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—sarcoma	1.56e-05	3.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2—sarcoma	1.53e-05	2.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NRAS—sarcoma	1.53e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—SRC—sarcoma	1.52e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—sarcoma	1.52e-05	2.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MDM2—sarcoma	1.52e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KIT—sarcoma	1.5e-05	2.94e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—KRAS—sarcoma	1.5e-05	2.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—sarcoma	1.49e-05	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—sarcoma	1.48e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—sarcoma	1.48e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—sarcoma	1.47e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—sarcoma	1.47e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—SRC—sarcoma	1.47e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—sarcoma	1.47e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—sarcoma	1.47e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—sarcoma	1.46e-05	2.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—sarcoma	1.45e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MDM2—sarcoma	1.44e-05	2.82e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—sarcoma	1.44e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KDR—sarcoma	1.44e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—sarcoma	1.43e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CREB1—sarcoma	1.43e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—sarcoma	1.43e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—sarcoma	1.43e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—sarcoma	1.42e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—sarcoma	1.41e-05	2.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—JUN—sarcoma	1.4e-05	2.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—sarcoma	1.4e-05	2.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KDR—sarcoma	1.39e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—sarcoma	1.39e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CTNNB1—sarcoma	1.39e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KIT—sarcoma	1.39e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—sarcoma	1.39e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—JUN—sarcoma	1.38e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CTNNB1—sarcoma	1.37e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—sarcoma	1.37e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MDM2—sarcoma	1.37e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—sarcoma	1.37e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—sarcoma	1.37e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—JUN—sarcoma	1.36e-05	2.66e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—sarcoma	1.36e-05	2.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KDR—sarcoma	1.35e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—sarcoma	1.35e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTNNB1—sarcoma	1.35e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MDM2—sarcoma	1.35e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1R—sarcoma	1.34e-05	2.62e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—sarcoma	1.34e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CREB1—sarcoma	1.32e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KIT—sarcoma	1.32e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—JUN—sarcoma	1.32e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—sarcoma	1.32e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—sarcoma	1.31e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTNNB1—sarcoma	1.31e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—sarcoma	1.3e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—sarcoma	1.29e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KIT—sarcoma	1.28e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—sarcoma	1.28e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FOXO1—sarcoma	1.28e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—sarcoma	1.28e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PDGFRB—sarcoma	1.27e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—sarcoma	1.27e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—sarcoma	1.26e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—sarcoma	1.26e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CREB1—sarcoma	1.26e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—SRC—sarcoma	1.26e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PDGFRA—sarcoma	1.25e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—sarcoma	1.25e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CTNNB1—sarcoma	1.25e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KIT—sarcoma	1.25e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SRC—sarcoma	1.24e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—sarcoma	1.24e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—sarcoma	1.22e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CREB1—sarcoma	1.22e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—SRC—sarcoma	1.22e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—sarcoma	1.22e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—sarcoma	1.21e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—sarcoma	1.21e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—sarcoma	1.2e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—sarcoma	1.19e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—sarcoma	1.19e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—JUN—sarcoma	1.19e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CREB1—sarcoma	1.19e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MDM2—sarcoma	1.19e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—SRC—sarcoma	1.18e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—sarcoma	1.18e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—sarcoma	1.17e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—sarcoma	1.17e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—JUN—sarcoma	1.17e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—sarcoma	1.17e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—sarcoma	1.16e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—sarcoma	1.16e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—sarcoma	1.16e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—sarcoma	1.14e-05	2.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SRC—sarcoma	1.13e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—sarcoma	1.12e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—sarcoma	1.11e-05	2.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—sarcoma	1.1e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—sarcoma	1.1e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MDM2—sarcoma	1.09e-05	2.14e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—sarcoma	1.09e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—sarcoma	1.08e-05	2.12e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—sarcoma	1.08e-05	2.12e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—sarcoma	1.07e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—sarcoma	1.07e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SRC—sarcoma	1.07e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—sarcoma	1.06e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—sarcoma	1.06e-05	2.06e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SRC—sarcoma	1.05e-05	2.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MDM2—sarcoma	1.04e-05	2.04e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—sarcoma	1.04e-05	2.03e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—sarcoma	1.04e-05	2.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—sarcoma	1.04e-05	2.03e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—sarcoma	1.04e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—JUN—sarcoma	1.03e-05	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—sarcoma	1.03e-05	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—sarcoma	1.03e-05	2.01e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—sarcoma	1.02e-05	2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—sarcoma	1.02e-05	2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MDM2—sarcoma	1.01e-05	1.98e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—sarcoma	1.01e-05	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—sarcoma	1.01e-05	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—sarcoma	1.01e-05	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—sarcoma	9.87e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MDM2—sarcoma	9.81e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—sarcoma	9.79e-06	1.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—sarcoma	9.73e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—sarcoma	9.73e-06	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—sarcoma	9.57e-06	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—sarcoma	9.44e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—sarcoma	9.41e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—sarcoma	9.39e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—sarcoma	9.36e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—sarcoma	9.32e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—sarcoma	9.31e-06	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREB1—sarcoma	9.26e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—sarcoma	9.24e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—sarcoma	9.2e-06	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—sarcoma	9.13e-06	1.79e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—sarcoma	9.07e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—sarcoma	9.05e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—sarcoma	9.03e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—sarcoma	8.98e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—sarcoma	8.89e-06	1.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—sarcoma	8.86e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—sarcoma	8.84e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—sarcoma	8.84e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—sarcoma	8.81e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—sarcoma	8.79e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—sarcoma	8.76e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—sarcoma	8.74e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—sarcoma	8.72e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—sarcoma	8.7e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—sarcoma	8.58e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—sarcoma	8.54e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—sarcoma	8.53e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—sarcoma	8.52e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—sarcoma	8.46e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—sarcoma	8.37e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—sarcoma	8.32e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—sarcoma	8.21e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—sarcoma	8.12e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—sarcoma	8.1e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—sarcoma	7.92e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—sarcoma	7.91e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—sarcoma	7.88e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—sarcoma	7.86e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—sarcoma	7.81e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—sarcoma	7.73e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—sarcoma	7.68e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—sarcoma	7.66e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—sarcoma	7.65e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—sarcoma	7.65e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—sarcoma	7.64e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—sarcoma	7.58e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—sarcoma	7.52e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—sarcoma	7.48e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—sarcoma	7.45e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—sarcoma	7.39e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—sarcoma	7.36e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—sarcoma	7.28e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—sarcoma	7.17e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HBA1—sarcoma	7.12e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—sarcoma	7.12e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—sarcoma	7.12e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—sarcoma	7.06e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—sarcoma	7.06e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—sarcoma	6.91e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—sarcoma	6.85e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—sarcoma	6.85e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—sarcoma	6.72e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—sarcoma	6.7e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—sarcoma	6.67e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—sarcoma	6.66e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—sarcoma	6.61e-06	1.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—sarcoma	6.53e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—sarcoma	6.5e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—sarcoma	6.33e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLCG1—sarcoma	6.08e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—sarcoma	6e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—sarcoma	5.98e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—sarcoma	5.97e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—sarcoma	5.82e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—sarcoma	5.8e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—sarcoma	5.75e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—sarcoma	5.71e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—sarcoma	5.63e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—sarcoma	5.55e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—sarcoma	5.38e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—sarcoma	5.35e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—sarcoma	5.24e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—sarcoma	4.95e-06	9.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—sarcoma	4.4e-06	8.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—sarcoma	4.2e-06	8.22e-06	CbGpPWpGaD
